Last reviewed · How we verify
Quadrivalent Influenza High-Dose Vaccine
Quadrivalent Influenza High-Dose Vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 1 development. Also known as: Fluzone High-Dose Quadrivalent®.
At a glance
| Generic name | Quadrivalent Influenza High-Dose Vaccine |
|---|---|
| Also known as | Fluzone High-Dose Quadrivalent® |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer (PHASE1)
- Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quadrivalent Influenza High-Dose Vaccine CI brief — competitive landscape report
- Quadrivalent Influenza High-Dose Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Quadrivalent Influenza High-Dose Vaccine
What is Quadrivalent Influenza High-Dose Vaccine?
Quadrivalent Influenza High-Dose Vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Quadrivalent Influenza High-Dose Vaccine?
Quadrivalent Influenza High-Dose Vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
Is Quadrivalent Influenza High-Dose Vaccine also known as anything else?
Quadrivalent Influenza High-Dose Vaccine is also known as Fluzone High-Dose Quadrivalent®.
What development phase is Quadrivalent Influenza High-Dose Vaccine in?
Quadrivalent Influenza High-Dose Vaccine is in Phase 1.
Related
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Also known as: Fluzone High-Dose Quadrivalent®
- Compare: Quadrivalent Influenza High-Dose Vaccine vs similar drugs
- Pricing: Quadrivalent Influenza High-Dose Vaccine cost, discount & access